Plasma Taurine in Older Women With Obesity: Impact of Metabolic Phenotype and Combined Exercise

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age60-75
SponsorUniversity of Sao Paulo

About this trial

Population aging has been accompanied by a rise in obesity and other chronic diseases, increasing cardiovascular risk particularly among women, who exhibit a higher prevalence in older age groups compared to men. Aging and obesity share pathophysiological mechanisms, such as chronic inflammation and oxidative stress. However, distinct obesity phenotypes exist, such as metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). Consequently, therapeutic interventions involving nutritional strategies and physical training are highly relevant, especially for older women. Taurine, a sulfur-containing amino acid, plays a role in modulating oxidative stress, inflammation, osmoregulation, and mitochondrial function. Rationale: Plasma taurine concentrations are lower in women with obesity compared to healthy individuals. However, studies investigating these concentrations across different phenotypes-particularly in older women, a group susceptible to functional and metabolic changes-remain limited. Understanding these variations could clarify taurine's role in the pathophysiology of obesity and aging and inform personalized therapeutic strategies. Combined physical training stands out as an effective strategy for modulating inflammatory, oxidative, and metabolic pathways, in addition to improving psychosocial aspects. Given that taurine levels can be influenced by these pathways, investigating the taurine response to physical training across different metabolic phenotypes may contribute to developing low-cost interventions aimed at improving the quality of life for older women with obesity.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Women aged 60 to 75 years.

Residents of the city or region of Ribeirão Preto, São Paulo, Brazil.

Physically inactive for at least 3 months.

Body mass index (BMI) ≥ 30 kg/m² (PAHO, 2002).

Disqualifiers

Contraindication to physical exercise.

Neoplasms;

Autoimmune diseases;

Hepatic diseases;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Physical Training of 16 weeks

    Behavioral

    Combined physical Training during 16 weeks

Treatment groups

36 Participants
are divided into 2 treatment groups
Group A: Metabolically Healthy Obesity (MHO)Other 1 intervention
Group B: Metabolically Unhealthy Obesity (MUO)Other 1 intervention

Trial outcomes

Primary outcomes

1

Plasma taurine concentrations (µmol/L).

It will be analyzed by high-performance liquid chromatography.

Time frame
16 weeks

Secondary outcomes

1

Systolic and diastolic blood pressure (mmHg)

Using sphygmomanometer

Time frame
16 weeks
2

Waist and hip circumferences (cm)

non-stretch anthropometric tape

Time frame
16 weeks
3

Appendicular lean soft tissue (kg).

Using Dual-energy X-ray Absorptiometry (DXA), often referred to as iDXA, is a low-dose X-ray technology that measures bone mineral density (BMD) and body composition

Time frame
16 Weeks
4

Total and regional body fat percentage (%)

Dual-energy X-ray Absorptiometry

Time frame
16 weeks

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: